GeneHealth - Your precision medicine

Cystinuria

Disease Details

Family Health Simplified

Buy Membership

Description: Cystinuria is a genetic disorder characterized by the recurrent formation of cystine stones in the kidneys, ureters, and bladder due to defective renal tubular reabsorption of cystine and other dibasic amino acids.
Type: Cystinuria is an inherited disorder characterized by the excessive excretion of cystine in the urine, leading to the formation of cystine stones in the kidneys, ureter, and bladder. It is transmitted in an autosomal recessive manner.
Signs And Symptoms: ### Signs and Symptoms of Cystinuria

Cystinuria is a genetic disorder characterized by the excessive excretion of cystine in the urine, which can lead to the formation of cystine stones in the kidneys, ureters, and bladder. The primary signs and symptoms include:

- **Pain**: Severe or colicky pain in the lower back or abdomen due to kidney stones.
- **Hematuria**: Blood in the urine.
- **Recurrent Urinary Tract Infections (UTIs)**: Due to obstruction or injury caused by stones.
- **Urinary Urgency and Frequency**: Due to irritation or infection.
- **Nausea and Vomiting**: Often associated with severe pain.

As cystinuria is chronic, individuals may experience these symptoms repeatedly, especially if the condition is not well-managed. Regular monitoring and appropriate treatment are essential to manage the disorder and alleviate symptoms.
Prognosis: Cystinuria is a lifelong condition characterized by the formation of cystine stones in the kidneys, ureters, and bladder. The prognosis for individuals with cystinuria can vary. With proper management, including increased fluid intake, dietary modifications, and medication, the frequency and severity of stone formation can be reduced. However, individuals may continue to experience recurrent stone episodes and potential complications such as urinary tract infections or kidney damage. Regular monitoring and appropriate medical intervention are crucial for managing the condition effectively.
Onset: Cystinuria typically manifests in young adulthood, often between the ages of 10 and 30. It is a genetic condition characterized by the formation of cystine stones in the kidneys, ureters, and bladder.
Prevalence: Cystinuria is a rare inherited disorder characterized by high levels of cystine in the urine, leading to the formation of cystine stones in the kidneys, ureters, and bladder. Its prevalence is estimated to be approximately 1 in 7,000 to 1 in 10,000 individuals worldwide.
Epidemiology: Cystinuria is a genetic disorder that typically presents in early adulthood. It affects approximately 1 in 7,000 to 1 in 10,000 people worldwide, although the prevalence can vary between different populations. The disorder is characterized by the excessive excretion of cystine in the urine, leading to the formation of cystine stones in the kidneys, ureters, and bladder.
Intractability: Cystinuria is not inherently intractable, but it is a chronic condition that requires lifelong management. Treatments primarily focus on preventing kidney stones through increased fluid intake, dietary modifications, and medications to reduce cystine levels in the urine. In more severe cases, other interventions such as extracorporeal shock wave lithotripsy (ESWL) or surgery may be necessary to manage kidney stones. While cystinuria can be managed effectively, it typically requires ongoing attention and intervention to prevent complications.
Disease Severity: Cystinuria severity can vary significantly among affected individuals. Some people may have frequent and severe kidney stones, leading to intense pain, urinary tract infections, and potential kidney damage, while others may experience less frequent or milder symptoms. The condition is managed through hydration, dietary modifications, and medication to reduce cystine levels and prevent stone formation. In severe cases, surgical intervention to remove stones may be necessary.
Healthcare Professionals: Disease Ontology ID - DOID:9266
Pathophysiology: Cystinuria is characterized by the inadequate reabsorption of cystine in the proximal convoluted tubules after the filtering of the amino acids by the kidney's glomeruli, thus resulting in an excessive concentration of this amino acid in the urine. Cystine may precipitate out of the urine, if the urine is neutral or acidic, and form crystals or stones in the kidneys, ureters, or bladder. It is one of several inborn errors of metabolism included in the Garrod's tetrad. The disease is attributed to deficiency in transport and metabolism of amino acids.
Carrier Status: Cystinuria is an inherited genetic disorder characterized by the excessive excretion of the amino acid cystine into the urine, leading to the formation of cystine stones in the kidneys, ureter, and bladder. Carrier status refers to individuals who have one copy of the mutated gene responsible for cystinuria but do not exhibit symptoms of the disease. These individuals are carriers and can pass the mutated gene to their offspring. The condition follows an autosomal recessive inheritance pattern, meaning that an affected individual must inherit two copies of the mutated gene, one from each parent.
Mechanism: Cystinuria is a hereditary disorder characterized by the defective transport of cystine and other dibasic amino acids in the kidney and intestines. This defect leads to poorly soluble cystine accumulating and forming stones in the kidneys, ureters, and bladder.

**Mechanism:**
Cystinuria results from mutations in the SLC3A1 or SLC7A9 genes. These genes encode the subunits of the cystine transporter, located in the renal tubules and intestinal epithelial cells. Mutations lead to dysfunctional transport proteins, preventing cystine reabsorption in the kidneys and increasing cystine concentration in urine, where it can precipitate and form stones.

**Molecular Mechanisms:**
1. **Gene Mutations:** The primary molecular defect is mutations in either SLC3A1 or SLC7A9. SLC3A1 produces the heavy subunit (rBAT), and SLC7A9 encodes the light subunit (b0,+AT) of the cystine transporter.
2. **Transporter Dysfunction:** Mutations impair the function of the rBAT/b0,+AT heterodimer, disrupting the reabsorption of cystine and other dibasic amino acids such as lysine, arginine, and ornithine.
3. **Cystine Solubility:** Cystine's poor solubility in urine leads to supersaturation, crystal formation, and eventually stone formation, as cystine is a relatively insoluble amino acid.

The key to cystinuria's pathophysiology thus lies in the genetic and molecular disruptions that compromise cystine transport and increase its urinary excretion.
Treatment: Initial treatment is with adequate hydration, alkalization of the urine with citrate supplementation or acetazolamide, and dietary modification to reduce salt and protein intake (especially methionine). If this fails then patients are usually started on chelation therapy with an agent such as penicillamine. Tiopronin is another agent.
Once renal stones have formed, however, the first-line treatment is endoscopic laser lithotripsy. ESWL (Extracorporeal shock wave lithotripsy) is often not effective because of the hardness of the stones that do not fragment easily. Conventional open-abdominal surgery is rarely used but has proven to be effective treatment modalities for patients with more advanced disease. Adequate hydration is the foremost aim of treatment to prevent cystine stones. The goal is to increase the urine volume because the concentration of cystine in the urine is reduced which prevents cystine from precipitating from the urine and forming stones. People with cystine stones should consume 5 to 7 liters a day. The rationale behind alkalizing the urine is that cystine tends to stay in solution and causes no harm. In order to alkalize the urine, sodium bicarbonate has been used. One must be careful in alkalizing their urine because it could lead to other forms of stones in process of preventing cystine stones. Penicillamine is a drug that acts to form a complex with cystine that is 50 times more soluble than cystine itself. Percutaneous nephrolithotripsy (PNL) is performed via a port created by puncturing the kidney through the skin and enlarging the access port to 1 cm in diameter. Most of the time, cystine stones are too dense to be broken up by shock (ESWL) so PNL is needed.Videos of surgery are available on various websites that show stone removal by percutaneous nephrolithotomy.In February 2017, an article was published in Nature Medicine entitled "Alpha lipoic acid treatment prevents cystine urolithiasis in a mouse model of cystinuria", suggesting that a high dose of the readily available antioxidant, alpha-lipoic acid at 2,700 mg/67 kg body weight daily reduced the incidence of stones. The effects were dose dependent. The results are unprecedented for cystinuria. A clinical trial is underway based on this mouse model.
Compassionate Use Treatment: Cystinuria is a genetic disorder characterized by the excessive excretion of cystine in the urine, leading to the formation of cystine stones in the kidneys, ureters, and bladder. While standard treatments include hydration, alkalinization of urine, and cystine-binding thiol drugs, there are also some off-label or experimental treatments being explored:

1. **Tiopronin and D-penicillamine**: These drugs are used off-label to bind cystine and increase its solubility in urine, thereby reducing stone formation.

2. **Lithotripsy**: Though not specifically for cystinuria, extracorporeal shock wave lithotripsy (ESWL) can be used to break up large cystine stones.

3. **New Molecules and Therapies**: Research is ongoing into new compounds that might inhibit cystine stone formation or improve cystine solubility.

4. **Genetic and Enzyme Therapies**: Future experimental treatments may involve gene editing or enzyme replacement therapies to correct the underlying genetic defect responsible for cystinuria.

Utilizing off-label or experimental treatments should always involve close consultation with a healthcare provider specialized in metabolic or genetic disorders.
Lifestyle Recommendations: For cystinuria, the primary lifestyle recommendations include:

1. **Hydration**: Increase water intake to produce at least 3 liters of urine per day. This helps dilute the concentration of cystine in urine and reduces the risk of stone formation.
2. **Dietary modifications**: Limit sodium and animal protein intake as both can increase cystine levels in the urine.
3. **Medications**: Take prescribed medications as directed by a healthcare provider to help dissolve cystine stones or prevent their formation.
4. **Regular monitoring**: Regular follow-up with a healthcare provider to monitor kidney function and adjust treatment as necessary.

Lifestyle adjustments alone may not fully manage cystinuria, so it is important to work closely with a healthcare professional.
Medication: For cystinuria, medication options may include:

1. **Penicillamine**: Helps to reduce cystine levels in the urine by forming a more soluble compound.
2. **Tiopronin**: Similar to penicillamine, it helps make cystine more soluble in urine.
3. **Potassium citrate**: Helps to alkalinize the urine, reducing cystine solubility and thereby preventing stone formation.

Close management with a healthcare provider is necessary to monitor and adjust treatment as needed.
Repurposable Drugs: Cystinuria is a genetic condition characterized by the abnormal transport of cystine, an amino acid, leading to the formation of cystine stones in the kidneys. Drugs repurposable for managing cystinuria include:

1. Penicillamine: Originally used for treating rheumatoid arthritis and Wilson's disease, penicillamine helps to reduce cystine levels in urine by forming a soluble complex with cystine.
2. Captopril: An antihypertensive medication that can also form a soluble complex with cystine, potentially reducing stone formation.

These options can be considered for managing the condition under proper medical guidance. Regular hydration and urinary alkalinization with potassium citrate are also key components of cystinuria management.
Metabolites: For cystinuria, the primary metabolite of concern is cystine. Cystinuria is a genetic disorder that results in the defective transport of certain amino acids, specifically cystine, lysine, arginine, and ornithine, in the kidneys and intestines. Reduced reabsorption of cystine in the kidneys leads to high concentrations in the urine, which can form cystine stones.
Nutraceuticals: Cystinuria is a genetic disorder characterized by the excessive excretion of cystine in the urine, leading to the formation of cystine stones in the kidneys. For managing cystinuria, nutraceuticals such as potassium citrate and magnesium citrate can help alkalinize the urine and increase cystine solubility, reducing stone formation. N-acetylcysteine (NAC) may also be beneficial due to its potential to reduce cystine stone formation in some cases.

Nanotechnology (nan) remains an emerging field in the context of cystinuria. Current studies focus on the development of nanoparticles that could target and dissolve cystine crystals or improve the delivery of therapeutic agents directly to the kidneys, but practical clinical applications are still under research and development stages.
Peptides: Cystinuria is a genetic disorder that affects the transport of certain amino acids, including cystine, in the kidneys and intestines. This leads to the formation of cystine stones in the kidneys, ureter, and bladder. Cystine is poorly soluble in urine, resulting in stone formation. Management strategies include maintaining high fluid intake, alkalinizing the urine, and using medications such as tiopronin or penicillamine to reduce cystine levels. Regular monitoring and dietary adjustments to limit cystine and other stone-forming substances may also be recommended.